APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    Adagene Raises $69 Million for Immunotherapies

    The round brings the company's total raised fund to more than $150 million and will push its leading immunotherapies through the clinic and aid better in the development of drug discovery technology.  

    Adagene Raises $69 Million for Immunotherapies

    By

    Apac CIOOutlook | Tuesday, March 24, 2020

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    The round brings the company's total raised fund to more than $150 million and will push its leading immunotherapies through the clinic and aid better in the development of drug discovery technology.

    FREMONT, CA: Adagene, Inc., a China-based clinical-stage oncology immunotherapy company, closed a $69 million Series D round of financing. The round was led by US Global growth equity firm General Atlantic which also made a $50 million investment. Other investors included Eight Roads Ventures China, F-Prime Capital, WuXi Corporate Venture Fund, and Sequoia China.

    The company raised more than $150 million in total, which will drive its lead immunotherapies through the clinic and aid better in the development of its drug discovery technology.

    “Strong support from our new and existing investors endorses Adagene’s technology platform and strategy to develop differentiated immunotherapies in areas where others have failed,” said Peter Luo, Ph.D., Co-founder and Chief Executive Officer of Adagene. “This financial commitment enables us to continue developing our lead clinical programs, ADG106 and ADG116, while extending the frontiers of our novel technology. We look forward to advancing our clinical pipeline and exploring strategic and synergistic opportunities to facilitate long-term sustainable growth.”

    The funding will boost its programs of ADG106 and ADG116 and develop its technology. ADG106, an anti-CD137 targeting antibody, which is in Phase 1 studies in the U.S. and China, in solid tumors and blood cancer that are in advanced stage. Following after is ADG116, an anti-CTLA-4 antibody that has a novel mechanism of action, including dynamic modulation of CTLA-4 by soft ligand blocking and highly effective depletion of regulatory T cells.

    “We believe China is a rising, vibrant hub for global life sciences innovation. Adagene represents a new-generation biotechnology company that is driving global innovation. Its cutting-edge Dynamic Precision Library platform, combined with its dedicated founders and management team, allows Adagene to advance assets of true novelty to the value inflection point,” said Lefei Sun, managing director and head of Healthcare for China at General Atlantic. “We are proud to partner with Adagene as we increase our commitment to the life sciences industry in China.”

    More in News

    Impact of Digital Transformation on Retail

    Impact of Digital Transformation on Retail

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    Salesforce Services in APAC: Empowering Digital Transformation Across the Region

    Salesforce Services in APAC: Empowering Digital Transformation Across the Region

    Enhancing Customer Satisfaction through Omni-Channel Payments

    Enhancing Customer Satisfaction through Omni-Channel Payments

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/adagene-raises-69-million-for-immunotherapies-nwid-7302.html